Clinical characteristics and long-term survival of early breast cancer cases in the American University of Beirut Medical Center, Beirut, Lebanon

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 833-833
Author(s):  
A. Shamseddine ◽  
M. Seoud ◽  
J. Abbas ◽  
M. Charafeddine ◽  
Z. Salem ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Clinical Characteristics ◽  
Medical Center ◽  
Term Survival ◽  
Long Term Survival ◽  
American University ◽  
American University Of Beirut

Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial

2005 ◽  
Vol 23 (12) ◽  
pp. 2686-2693 ◽  
Author(s):  
Jacques Bonneterre ◽  
Henri Roché ◽  
Pierre Kerbrat ◽  
Alain Brémond ◽  
Pierre Fumoleau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Poor Prognosis ◽  
Cardiac Toxicity ◽  
Study Group ◽  
Term Survival ◽  
Long Term Survival ◽  
Patients With Poor Prognosis

Purpose The French Adjuvant Study Group 05 (FASG-05) showed that fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2 (FEC 100) was superior to the same regimen with epirubicin 50 mg/m2 (FEC 50) in terms of disease-free survival (DFS) and overall survival (OS) in adjuvant treatment of early breast cancer. We report 10-year data on efficacy, and long-term side effects for FASG-05. Patients and Methods We randomly assigned 565 patients to treatment with FEC 50 or FEC 100 after surgery. Postmenopausal patients also received tamoxifen for 3 years, and almost all patients (96%) also received radiotherapy. Results Median follow-up was 110 months. The 10-year DFS was 45.3% (95% CI, 41.9% to 48.7%) with FEC 50 and 50.7% (95% CI, 47.3% to 54.1%) with FEC 100 (Wilcoxon P = .036; log-rank P = .08). The 10-year OS was 50.0% (95% CI, 46.7% to 53.3%) with FEC 50 and 54.8% (95% CI, 51.3% to 58.3%) with FEC 100 (Wilcoxon P = .038; log-rank P = .05). Delayed cardiac toxicity (before relapse) occurred in four patients (1.5%) in the FEC 50 arm and three patients (1.1%) in the FEC 100 arm. Cardiac toxicity after relapse occurred in six (4.3%) and five (4.1%) patients treated with FEC 50 and FEC 100, respectively. Conclusion Treatment with adjuvant FEC 100 demonstrated superior DFS and OS versus FEC 50 at 10 years of follow-up. This survival advantage was not offset by long-term complications such as cardiac toxicity and second malignancy. Given the risk-benefit ratio, FEC 100 is a more optimal regimen for long-term survival in patients with poor prognosis.

Quality of patient-reported outcome for long-term survival of early breast cancer trials.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e18121-e18121
Author(s):  
Gunter Von Minckwitz ◽  
Jan Steffen ◽  
Serban Dan Costa ◽  
Wolfgang Janni ◽  
Marc Thill ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Patient Reported Outcome ◽  
Term Survival ◽  
Long Term Survival ◽  
Patient Reported ◽  
Cancer Trials

scholarly journals Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice

The Breast ◽  
2014 ◽  
Vol 23 (5) ◽  
pp. 573-578 ◽  
Author(s):  
Martina Bonifazi ◽  
Matteo Franchi ◽  
Marta Rossi ◽  
Alberto Zambelli ◽  
Lorenzo Moja ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Clinical Practice ◽  
Early Breast Cancer ◽  
Large Cohort ◽  
Her2 Positive ◽  
Term Survival ◽  
Long Term Survival ◽  
Large Cohort Study
Sign in / Sign up

Export Citation Format

Share Document